Compare MBBC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | GBIO |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | MBBC | GBIO |
|---|---|---|
| Price | $12.18 | $5.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | 2.2K | ★ 72.1K |
| Earning Date | 02-22-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $7,299,708.00 | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $106.88 | ★ N/A |
| Revenue Growth | ★ 7.77 | N/A |
| 52 Week Low | $8.74 | $3.00 |
| 52 Week High | $12.89 | $12.40 |
| Indicator | MBBC | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 45.94 |
| Support Level | $11.93 | $5.31 |
| Resistance Level | $12.40 | $5.77 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 77.60 | 23.08 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.